Codex DNA Reports Second Quarter 2022 Financial Results
August 09, 2022 16:10 ET
|
Codex DNA, Inc.
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended...
Codex DNA to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
August 02, 2022 16:05 ET
|
Codex DNA, Inc.
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its second quarter 2022...
Codex DNA to Present at the 2022 Jefferies Healthcare Conference
June 02, 2022 08:03 ET
|
Codex DNA, Inc.
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company’s chief...
Codex DNA Showcases Automated Synthetic Biology Solutions for Accelerating Discovery Workflows at the Antibody Engineering and Therapeutics Europe Conference
June 01, 2022 08:03 ET
|
Codex DNA, Inc.
BioXp™ system and RapidAMP™ cell-free DNA kit rapidly accelerate antibody discovery pipelines by addressing critical bottlenecks associated with lead candidate gene synthesis, cloning, and scale-up ...
Codex DNA Reports First Quarter 2022 Financial Results
May 10, 2022 16:05 ET
|
Codex DNA, Inc.
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the first quarter ended...
Codex DNA to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
May 03, 2022 08:03 ET
|
Codex DNA, Inc.
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its first quarter 2022...
Codex DNA Unveils Automated Synthetic Biology Solutions for Antibody and Protein Engineering of Biotherapeutic Targets at 18th Annual PEGS Boston Conference and Expo
April 27, 2022 08:03 ET
|
Codex DNA, Inc.
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its speaker lineup for presentations at the...
Codex DNA Demonstrates End-to-End Workflow for Storing and Retrieving Data in Synthetic DNA
April 26, 2022 08:03 ET
|
Codex DNA, Inc.
SAN DIEGO, April 26, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the completion of proof-of-concept...
Codex DNA Demonstrates Simple, Scalable, and Cell-Free Approach to Rapid mRNA Vaccine Design and Development at World Vaccine Congress Washington 2022
April 18, 2022 15:47 ET
|
Codex DNA, Inc.
SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its speaker presentation for the World...
Codex DNA to Showcase Innovative SOLA Enzymatic DNA Synthesis Technology and Automated Benchtop BioXp System at SynBioBeta’s Built with Biology Global Conference
April 06, 2022 08:03 ET
|
Codex DNA, Inc.
SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its speaker lineup for presentations at...